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Abstract Novel peptides containing the sequence -Pro-Leu-
Ama(NHOH)- were synthesized and characterized by spectro-
scopic techniques. Their inhibitory properties towards the
activated form of native human gelatinase B (MMP-9) and the
catalytic domain of neutrophil collagenase (cdMMP-8) were
determined. The most effective inhibitor synthesized exhibits Ki
values of 2U1036 M (cdMMP-8) and 5U1039 M (MMP-9)
thus attaining interesting discrimination between the tested
metalloproteinases. A most important feature of this type of
inhibitor is its peptide nature making the compounds similar to
natural substrates. In spite of the peptide character of the
inhibitors synthesized, the P1-P1P-peptide bond shows a high
resistance to cleavage by the proteinases.
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1. Introduction
Matrix metalloproteinases (MMPs) are a family of at least
15 zinc-containing proteinases playing a fundamental role in
the degradation and remodelling of connective tissue by hy-
drolysis of matrix proteins such as collagens, gelatins and
proteoglycans [1]. In this way MMPs are involved in many
pathophysiological processes connected to extracellular matrix
disintegration, e.g. rheumatoid arthritis or tumor invasion and
metastasis. Matrix metalloproteinases have similar domain
structures including as major domains an N-terminal prodo-
main, the catalytic domain and, in most cases, a hemopexin
domain in some species involved in substrate speci¢city. The
metalloproteinases are produced as zymogens and activated
by removal of the prodomain, e.g. by organomercuric agents
and autolytic cleavage or by other proteases. MMPs are div-
ided into several subgroups based on their domain structures,
sequence homologies and their substrate preferences. Tissue
inhibitors of metalloproteinases (TIMPs), naturally occurring
proteins speci¢cally inhibiting these proteinases, control
MMPs in vivo. An imbalance between MMPs and their nat-
ural antagonists, the TIMPs, can result in pathophysiological
destructive processes such as rheumatoid arthritis, parodonto-
sis or ¢brosis. This may be compensated with potent synthetic
inhibitors. Numerous synthetic low-molecular weight MMP
inhibitors have been synthesized [2,3] and research is currently
being carried out on their in vivo e⁄ciency in di¡erent kinds
of cancer or destructive joint diseases. Most of the synthetic
MMP inhibitors developed so far are small molecular com-
pounds binding to the catalytic site of the enzymes. Several X-
ray crystal structures of the catalytic domains of collagenases
complexed with an inhibitor have been published [4^7]. E¡ec-
tive inhibitors are equipped with a zinc chelator group and a
peptide or non-peptide backbone mimicking a natural sub-
strate. The hydroxamic acid function is a very good zinc-che-
lating group thus providing the most potent inhibitors of
MMPs. In general the hydroxamic acid-based inhibitors are
of the C-terminal type, binding at SP-subsites of the enzyme
(nomenclature Sn...SnP, Pn...PnP according to Schechter and
Berger [8]). N-terminal inhibitors are much less e¡ective.
For the most part, C-terminal hydroxamic acid inhibitors
are succinyl derivatives with various aliphatic or aromatic
substituents on either the K- or L-carbon or both and residues
at the Q-carboxyl function, attached by a peptide linkage.
In this paper a novel type of hydroxamic acid-based peptide
inhibitor is presented. The residue carrying the hydroxamate
function is an aminomalonic acid (Ama) in position P1. This
allows the addition of various residues suitable to gain max-
imum attachment to the entire binding site of the target en-
zyme on both S- and SP-subsites. The most important feature
of this type of inhibitor is the peptide backbone built up by K-
amino acids to comprise the positions P3 to P1P at least, giving
these compounds the same basic frame as a peptide substrate.
In accordance with the speci¢city of the metalloproteinases
tested the P3 position of these inhibitors is occupied by a
proline; P2 is an aliphatic amino acid, whereby leucine or
alanine is favored. The best inhibitory properties were ob-
tained with the bulky tyrosine benzylether moiety in the P1P
position (Fig. 1).
2. Materials and methods
2.1. Chemicals and equipment
Reagents and solvents were of p.a. quality from Fluka (Buchs),
Merck (Darmstadt) and Baker (Gross-Gerau). A Waters chromatog-
raphy system with Baker wide pore octadecyl column (C18, 5 Wm) was
used for analytical HPLC (5 min water with 0.1% TFA, gradient: 5^
45 min from 0 to 100% acetonitrile, water (80:20, v/v) with 0.09%
TFA). Analytical TLC was carried out on KG 60 F254 alu foil and
preparative layer chromatography on KG 60 F254 plates, 2 mm layer,
both from Merck.
Characterization of the synthesized inhibitors and precursors was
carried out using NMR (Bruker AC 250 P), ion spray mass spectro-
scopy (API III Quadrupol mass spectrometer with ion spray interface
from Sciex) or FAB mass spectroscopy (liquid-SIMS, positive ioniza-
tion, Autospec VG by Fisons). Enzyme inhibition assays were per-
formed using a spectro£uorometer Jasco FP-550 or a luminescence
spectrometer Perkin-Elmer LS 50B.
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2.2. Synthesis of the inhibitors
The peptides containing an Ama(OMe) residue were synthesized by
segment condensation of N-protected tripeptides of the type R1-Pro-
Aaa-Ama(OMe)OH and H-Tyr(Bzl)-R2, where R1 is a Boc protecting
group or acetyl, Aaa is glycine, alanine or leucine and R2 is an amide-
bonded S(3)-K-methylbenzylamine, R(+)-K-methylbenzylamine or
R(3)-K-methylcyclohexanemethylamine. Peptide coupling reactions
were carried out in organic solvents following standard procedures.
Alternatively an N-protected dipeptide Boc-Aaa-Ama(OMe)OH was
coupled with the C-terminal fragment and, after removal of the Boc
group, the R1-Pro was added using an active ester. The conversion of
the aminomalonic acid methyl ester function into the corresponding
hydroxamic acid was e¡ected via hydrolysis of the ester to the free
malonic acid and treatment with hydroxylamine hydrochloride, a ter-
tiary amine and DCC or directly by aminolysis of the methyl ester
with hydroxylamine [9].
The synthesis of Boc-Leu-Ama(OMe)OH described below is a typ-
ical procedure for the preparation of N-protected di or tripeptides
containing Ama(OMe)OH.
Preparation of Boc-Leu-Ama(OMe)2 : Boc-Leu-OH (5 mmol), ami-
nomalonic acid dimethyl ester hydrochloride (5 mmol) and triethyl
amine (5 mmol) were suspended in 50 ml of a mixture of THF, ethyl
acetate and dichloromethane (2:1:1, v/v). A solution of DCC (5
mmol) in 10 ml dichloromethane was added dropwise at 0‡C. The
mixture was stirred for about one hour at this temperature and
then at 5‡C until the end of the reaction (TLC control). After ¢ltra-
tion the solvent was removed in vacuo and the residue dissolved in
ethyl acetate. The solution was extracted with 5% aqueous Na2CO3,
10% NaHSO4 and 5% NaHCO3 solutions, dried with Na2SO4 and
evaporated. The crude product was dissolved in 15 ml dichlorome-
thane and stored at 0‡C for one day. The precipitated dicyclohexyl
urea was removed by ¢ltration and the solution was evaporated to
dryness. About 4.75 mmol (95%) Boc-Leu-Ama(OMe)2 was obtained.
TLC: Rf 0.7 (chloroform/methanol, 10:1, v/v).
NMR: 1H (250 MHz, CDCl3) : 0.95 (m, 6 H, CH3, Leu); 1.45 (s, 9
H, CH3, Boc); 1.52 (m, 1 H, Leu); 1.69 (m, 2 H, Leu); 3.81 (s, 6 H,
(OMe)2) ; 4.22 (m, 1 H, KCH, Leu); 4.94 (d, 1 H); 5.19 (d, 1 H); 7.18
(w, 1 H, NH, Ama).
13C (63 MHz, CDCl3) : 21.86; 22.97; 24.73; 28.30; 41.05 (CH2) ;
53.38; 56.08; 58.10; 81.05 (Cq) ; 166.50; 166.53; 172.59.
For the analogous synthesis of a tripeptide of the type Boc-Pro-
Aaa-Ama(OMe)2 the corresponding dipeptide Boc-Pro-Aaa-OH was
used.
Preparation of Boc-Leu-Ama(OMe)OH: To a solution of Boc-Leu-
Ama(OMe)2 (3 mmol) in 15 ml anhydrous methanol a solution of
KOH (2.9 mmol) in 2 ml methanol was added dropwise at 0‡C.
The reaction was carried out under nitrogen atmosphere. The mixture
was stirred at 0‡C for 3 h, then stirring was continued overnight at
room temperature. After evaporation, the residue was dissolved in 25
ml 5% aqueous NaHCO3. The solution was extracted with ether,
cooled to 0‡C, acidi¢ed with NaHSO4 and ¢nally extracted with ethyl
acetate several times. The combined extracts containing the malonic
acid derivative were dried with Na2SO4 and the solvent was removed
in vacuo at 25‡C maximum. Yield 2.4 mmol (80%). TLC: Rf 0.45
(chloroform/methanol/32% acetic acid/ethyl acetate, 5:3:1:4, v/v).
HPLC: Rt 34.9 min.
NMR: 1H (250 MHz, DMSO-D6) : 0.86 (m, 6 H, CH3, Leu); 1.46
(s, 9 H, CH3, Boc); 1.53 (m, 2 H, Leu); 1.62 (m, 1 H, Leu); 3.69 (s, 3
H, OMe); 4.10 (m, 1 H, KCH, Leu); 4.98 (d, 1 H, KCH, Ama); 6.95
(t, 1 H); 8.39 (m, 1 H).
13C (63 MHz, DMSO-D6) : 21.29; 22.93; 24.14; 28.09; 40.43
(CH2) ; 52.32; 52.53; 55.99; 56.04; 78.05 (Cq) ; 155.24; 167.24;
167.30; 172.81.
The coupling of Boc-Aaa-Ama(OMe)OH or Boc-Pro-Aaa-Ama(O-
Me)OH derivatives with the C-terminal fragment was carried out in
dichloromethane with DCC and the product isolated as described
above. If necessary the crude product subsequently should be sepa-
rated by chromatography over Sephadex LH20 in methanol.
Deprotection of the peptides of the type Boc-Aaa-Ama(OMe)-
Tyr(Bzl)-R2 and subsequent addition of the N-protected proline oc-
curred via acid catalyzed hydrolysis of the Boc-protecting group: the
N-protected peptide (about 0.5 mmol) was dissolved or suspended in
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Fig. 1. Partial sequence of a typical substrate of gelatinase B (MMP-9) with the amino acid residues numbered according to Schechter and
Berger [8] compared with the structure of an inhibitor of the type R1-Pro-Leu-Ama(NHOH)-Tyr(Bzl)-R2 presumably binding at the subsites of
the enzyme. R1 is a protecting group, H, acetyl or an amino acid, R2 is an amine, an alcohol, NHOH or a C-terminal protected amino acid or
peptide.
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7 ml 2,2,2-tri£uoroethanol and 0.7 ml half concentrated HCl was
added. The mixture was stirred until the end of the reaction (TLC-
control), than poured into cold 5% aqueous NaHCO3. The aqueous
solution was extracted with ethyl acetate several times, the organic
solutions were dried with Na2SO4 and Boc-Pro-OSu was added. After
extraction of the organic solution and chromatographical separation
the pure peptide was obtained in high yields.
Preparation of the free aminomalonic acid derivatives occurred via
hydrolysis of the methyl ester dissolved in methanol with 2 M NaOH
at 0‡C. When TLC indicated total disappearance of the methyl ester,
the mixture was poured into 5% NaHCO3 and the product was ex-
tracted with ethyl acetate.
General procedures for the synthesis of the hydroxamic acid deriv-
atives:
(i) The peptide of the type Boc-Pro-Aaa-Ama(OH)-Tyr(Bzl)-R2 (0.1
mmol) was dissolved in 5 ml of a mixture of dichloromethane and
ethyl acetate (4:1, v/v), a tertiary amine (preferably triethyl amine, N-
ethyl or N-methyl morpholine, 0.12 mmol) and hydroxylamine hydro-
chloride (0.1 mmol) in DMF and DCC (0.11 mmol) were added at
0‡C. The mixture was stirred at 5‡C overnight, ¢ltered and evapo-
rated. The solution of the residue in ethyl acetate was extracted with
10% KHSO4, 5% NaHCO3 (which in some cases resulted in precip-
itation of the hydroxamic acid salt in the organic layer) and 10%
KHSO4, dried with Na2SO4 and the solvent was removed in vacuo.
The crude product was puri¢ed via preparative layer chromatography
(chloroform/methanol, 10:1, v/v).
(ii) The peptide containing aminomalonic acid methyl ester was
dissolved in anhydrous methanol. To the solution hydroxylamine hy-
drochloride (about 5 molar equivalents) was added and the mixture
was made strongly alkaline with sodium methanolate, added in small
portions. Stirring at 5‡C overnight caused total aminolysis of the
methyl ester by hydroxylamine. At 0‡C 10% NaHSO4 was added
and the product was extracted with ethyl acetate.
Properties of the compounds listed in Table 1:
(1) TLC: Rf 0.65 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.2 (chloroform/methanol, 10:1, v/v). HPLC: Rt
42.5 min. MS: ion spray m/z 767.4 (M+Na), 745.4 (M+H), 645.4
(M-Boc+H).
(2) TLC: Rf 0.63 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.17 (chloroform/methanol, 10:1, v/v). HPLC:
Rt 42.2 min. MS: ion spray m/z 767.4 (M+Na), 745.4 (M+H),
645.4 (M-Boc+H).
(3) TLC: Rf 0.7 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.42 (chloroform/methanol, 10:1, v/v). HPLC:
Rt 44.8 min. MS: FAB (matrix glycerol, CsI admixture) m/z 883
(M+Cs), 751 (M+H), 651 (M-Boc+H) ; ion spray m/z 773.4
(M+Na), 751.4 (M+H), 651.4 (M-Boc+H).
(4) TLC: Rf 0.75 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.3 (chloroform, methanol, 10:1, v/v). HPLC:
Rt 42.6 min. MS: ion spray m/z 781.5 (M+Na), 659.5 (M-Boc+H).
(5) TLC: Rf 0.75 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.5 (chloroform/methanol, 10:1, v/v). HPLC: Rt
46.9 min. MS: ion spray m/z 823.6 (M+Na), 801.4 (M+H), 701.4
(M-Boc+H). NMR: 1H (250 MHz, DMSO-D6) : 0.85 (m, 6 H, CH3,
Leu); 1.21^1.37 (m, 12 H, CH3 : Boc, CH(Ph)CH3) ; 1.4^2.15 (m, 7 H:
CH2, CtH, Leu; LCH2, QCH2, Pro); 2.75^3.0 (m, 2 H, CH2, Tyr);
3.15^3.38 (m, 2 H, NCH2, Pro); 4.13 (m, 1 H); 4.34 (m, 1 H); 4.46 (m,
1 H); 4.78^4.90 (m, 2 H); 5.05 (s, 2 H, CH2, Bzl); 6.90 (d, 2 H,
arom.); 7.12 (t, 2 H, arom.); 7.20^7.45 (m, 10 H, arom.); 7.90 (m,
1 H); 8.05^8.16 (m, 2 H); 8.29 (d, 1 H); 9.10, 9.14 (s, 1 H); 10.56,
10.63 (s, 1 H).
(6) TLC: Rf 0.75 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.5 (chloroform/methanol, 10:1, v/v). HPLC: Rt
46.7 min. MS: ion spray m/z 823.5 (M+Na), 801.5 (M+H), 701.5
(M-Boc+H).
(7) TLC: Rf 0.75 (chloroform/methanol/32% acetic acid/ethyl ace-
tate, 5:3:1:4, v/v), Rf 0.5 (chloroform/methanol, 10:1, v/v). HPLC: Rt
49.7 min. MS: ion spray m/z 829.5 (M+Na), 807.5 (M+H), 707.5
(M-Boc+H).
2.3. Enzyme inhibition assays
The inhibition constants Ki of the inhibitors were determined for
the proteolytically activated form of native human gelatinase B
(MMP-9) [10] and the catalytic domain of neutrophil collagenase
(cdMMP-8) [11]. The substrate used, (7-methoxycoumarin-4-yl)ace-
tyl-Pro-Leu-Gly-Leu-(3-(2,4-dinitrophenyl)-L-2,3-diamino-propionyl)-
Ala-Arg-NH2 [12], is an internally quenched £uorescent peptide,
which is cleaved at the Gly-Leu bond by the tested metalloproteinases.
The resulting increase of £uorescence was measured at an excitation
wavelength of 328 nm and an emission wavelength of 393 nm.
The assay mixtures contained constant concentrations of the en-
zyme and 3% DMSO (as solvent for inhibitors and substrate) in
2 ml of bu¡er (0.1 M Tris-HCl, pH 7.5, 0.1 M NaCl, 10 mM CaCl2,
0.05% Brij 35). For at least three series with constant concentrations
of substrate (approx. 0.2^1 WM) and di¡erent concentrations of the
inhibitor every initial £uorescence increase, which is proportional to
the substrate concentration and corresponds to the remaining proteo-
lytic activity of the enzyme, was measured at 25‡C. The substrate
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Table 1
Tested inhibitors and their Ki values determined with gelatinase B (MMP-9) and the catalytic domain of the neutrophil collagenase (MMP-8)
in mol/l
Compound no. R2 R3 MMP-9 cdMMP-8
1 NH-R-CH(Ph)CH3 H 4.0U1037 6.5U1036
2 NH-S-CH(Ph)CH3 H s 1037 1.8U1035
3 NH-R-CH(c-C6H11)CH3 H s 1037 1.4U1035
4 NH-S-CH(Ph)CH3 CH3 5.0U1039 1.9U1036
5 NH-R-CH(Ph)CH3 CH2-CH-(CH3)2 5.0U1039 8.0U1037
6 NH-S-CH(Ph)CH3 CH2-CH-(CH3)2 5.0U1039 8.0U1037
7 NH-R-CH(c-C6H11)CH3 CH2-CH-(CH3)2 1.8U1038 2.5U1036
NH-R-CH(Ph)CH3, NH-S-CH(Ph)CH3 and NH-R-CH(C6H11)CH3 are N-bounded residues of R(+)-K-methylbenzylamine, S(3)-K-methylbenzyl-
amine, and R(3)-K-methylcyclohexanemethylamine.
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(predissolved 0.1 mg in 1 ml DMSO) was added after incubation of
the enzyme with the inhibitor in the bu¡er for at least 10 min. Ki
values were determined by the established method of Dixon [13].
Activation of the latent progelatinase B (MMP-9), isolated from
human neutrophils, was carried out in assay bu¡er by adding bovine
trypsin (50 Wl, 0.6 mg/ml) to the proenzyme (0.45 ml, 120 Wg/ml) and
incubating at 37‡C for 10 min. The trypsin was then inactivated with
aprotinin (50 Wl, 1.2 mg/ml).
3. Results and discussion
The Ki values of the synthesized MMP inhibitors deter-
mined in quantitative £uorometric assays are shown in Table
1. Some of these compounds exhibit very good inhibitory
properties against the enzymes tested. Analogous derivatives
with free carboxyl function, methyl or ethyl esters at the ami-
nomalonic acid instead of a hydroxamate in this position
show virtually no inhibitory e¡ect [9]. Thus it is obvious
that a zinc-complexing function is essential for a high a⁄nity
to the metalloproteinases. This observation con¢rms the as-
sumption that these inhibitors bind competitively to the cata-
lytic center, with the hydroxamic acid in a proper position to
chelate the zinc ion in the active site. The complexing group,
representing the complete side chain of the amino acid in
positon P1, is ¢xed as close as possible to the peptide back-
bone and to the reactive-site bond.
Apart from this favorable conformational arrangement of
the chelating group towards the metal ion another relevant
criterion for e¡ective inhibition is an optimal adjustment of
the backbone to a natural substrate. The P1-residue in a nat-
ural substrate is glycine. Its substitution by the aminomalonic
acid derivative only adds a small chelating function to the
peptide. Except for the Ama(NHOH)-residue in P1 position
this type of peptide inhibitor is highly variable on both N-
and C-terminal sides, thus allowing design of the rest of the
structure for an optimal ¢t into to the enzyme subsites.
Corresponding to the substrate speci¢city of the tested met-
alloproteinases, the P3-position of all inhibitors is occupied by
a proline. A substitution of the proline in compound 1 by a
Boc protecting group results in a decrease of the inhibition
constant by about two orders of magnitude for the MMP-9
and one order for the cdMMP-8.
Compounds 5, 6 and 7 with leucine at P2-position have the
strongest inhibitory e¡ect toward the catalytic domain of
MMP-8, in agreement with the sequences of various synthetic
peptide substrates of collagenases [14^16]. The inhibition con-
stants of these compounds for the gelatinase B are about two
orders of magnitude lower than those for the collagenase with
its high substrate discrimination.
A more distinct selectivity between MMP-9 and cdMMP-8
is shown by compound 4 with alanine at the P2-site
(Ki = 5U1039 M for MMP-9, 1.9U1036 for cdMMP-8).
Whereas the Ki value of 4 for the MMP-9 equals those of
the analogous leucine derivatives, a distinct decrease can be
observed for the cdMMP-8. There is a nearly 400-fold inhib-
itory discrimination of 4 between the two enzymes.
The glycine-containing derivates 1^3 inhibit the tested en-
zymes one to two orders of magnitude less e⁄ciently. Thus an
amino acid with a chiral center in position P2 seems to be
favorable. This e¡ect is more pronounced for MMP-9, there-
fore these inhibitors are less selective.
The compounds with the bulky K-methylcyclohexaneme-
thylamine at position P2P have weaker inhibitory e¡ects than
the aromatic analogues.
Despite their peptide character the inhibitors were resistant
to hydrolysis by the proteases as con¢rmed by HPLC inves-
tigations after incubation of the inhibitors with the metallo-
proteinases for several hours. None of the possible fragments
from cleavage of the Ama-Tyr-bond could be detected. Thus,
these inhibitors and especially the P1-P1P-peptide bond exhibit
a high resistance to cleavage by the proteinases.
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